Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25539657 | 0.85 | EPHA2 (0.46) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL20521472 | 0.83 | NPSR1 (0.43) | EPHA2GPR119PDK1BUB1 | |
| SCHEMBL20521818 | 0.81 | GPR119 (0.37) | GPR119USP30 | |
| SCHEMBL20521428 | 0.79 | USP30 (0.40) | GPR119USP30 | |
| SCHEMBL1183588 | 0.78 | L3MBTL1 (0.48) | USP30 | |
| SCHEMBL1184473 | 0.78 | L3MBTL1 (0.48) | USP30 | |
| SCHEMBL24933225 | 0.78 | EPHA2 (0.58) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL1852171 | 0.77 | PDK1 (0.51) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL8257042 | 0.77 | HRH3 (0.45) | — | |
| SCHEMBL13984639 | 0.76 | EPHA2 (0.50) | EPHA2ERBB2EPHB4P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | disclosed |
| CN-115991679-A | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115873022-A | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-110678472-B | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-01-24 | — | — | CN | disclosed |
| EP-4112623-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2023-01-04 | — | — | EP | disclosed |
| EP-3601296-B1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2022-05-25 | — | — | EP | disclosed |
| US-20210198281-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2021-07-01 | — | — | US | disclosed |
| US-20210198281-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2021-07-01 | — | — | US | disclosed |
| US-10995101-B2 | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers | ITEOS THERAPEUTICS SA (BE) | 2021-05-04 | — | — | US | disclosed |
| US-10995101-B2 | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers | ITEOS THERAPEUTICS SA (BE) | 2021-05-04 | — | — | US | disclosed |
| EP-3601296-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | Iteos Therapeutics (BE) | 2020-02-05 | — | — | EP | disclosed |
| CN-110678472-A | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯治疗公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20190276473-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2019-09-12 | — | — | US | disclosed |
| US-20190276473-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2019-09-12 | — | — | US | disclosed |
| WO-2018178338-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | ITEOS THERAPEUTICS (BE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995101-B2 | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers | ADORA2A, ADORA2B, ADORA3 | EPHA2 108/4885ERBB2 475/4885EPHB4 1154/4885 |
| US-20190276473-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | EPHA2 108/4885ERBB2 475/4885EPHB4 1154/4885 |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | EPHA2 108/4885ERBB2 475/4885EPHB4 1154/4885 |
| US-20210198281-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA3 | EPHA2 108/4885ERBB2 475/4885EPHB4 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.